Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer
Precision Eligible to Receive up to $227m in Upfront Economics and Milestone Payments for Azer-Cel in Addition to…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
16 Aug 23
Precision Eligible to Receive up to $227m in Upfront Economics and Milestone Payments for Azer-Cel in Addition to…
14 Aug 23
The FDA approval is based on the Phase 3 MAGNITUDE study, in which Akeega plus prednisone significantly improved…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
14 Aug 23
As part of the efforts to improve their solutions, CAS will integrate Molecule.one's deep learning models for better…
14 Aug 23
As part of the collaboration, Logomix will initially contribute genome editing capabilities to assist HebeCell in creating the…
14 Aug 23
The launched ABSORBABLE supplements range includes three proprietary combinations of Vitamin C, Vitamin D3 1000 IU, and Vitamin…
14 Aug 23
ZM008 is a human IgG1 monoclonal antibody against LLT1 (CLEC2D), which disrupts the interaction of LLT1-CD161 between human…
14 Aug 23
Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for $3.2bn upfront
11 Aug 23
Inversago’s lead asset, INV-202, specifically blocks the receptor protein CB1, which plays key role in metabolism and appetite…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
11 Aug 23
The FDA approval was based on results from the talquetamab Phase 2 MonumenTAL-1 study in which Talvey showed…
11 Aug 23
The investment will help Astellas to establish a significant presence in life science innovation hotspots in the world…